...
首页> 外文期刊>Clinics and research in hepatology and gastroenterology >The efficacy of tyrosine kinase inhibitor dasatinib on colonic mucosal damage in murine model of colitis
【24h】

The efficacy of tyrosine kinase inhibitor dasatinib on colonic mucosal damage in murine model of colitis

机译:酪氨酸激酶抑制剂达沙替尼对结肠炎小鼠模型结肠黏膜损伤的疗效

获取原文
获取原文并翻译 | 示例

摘要

Background and objective: Ulcerative colitis is an inflammatory condition of the colon in the gastrointestinal system. Currently, the most potent medications used for ulcerative colitis produce no response in 20-30% of cases. There is a need for more efficient and reliable medications. Tyrosine kinase inhibitors have shown efficacy in some inflammatory diseases. Although dasatinib, a tyrosine kinase inhibitor, suppresses proinflammatory cytokines in colonic tissue, there are a few cases of hemorrhagic colitis with dasatinib. There is no study investigating the effect of dasatinib on experimental colitis. We aimed to investigate the effect of dasatinib in a colitis model induced with acetic acid in our study.
机译:背景与目的:溃疡性结肠炎是胃肠系统中结肠的一种炎症。目前,用于溃疡性结肠炎的最有效药物在20%至30%的病例中无反应。需要更有效和可靠的药物。酪氨酸激酶抑制剂在某些炎症性疾病中已显示出功效。尽管酪氨酸激酶抑制剂dasatinib抑制结肠组织中的促炎细胞因子,但仍有少数dasatinib出血性结肠炎的病例。没有研究调查达沙替尼对实验性结肠炎的作用。我们的目的是研究达沙替尼在乙酸诱发的结肠炎模型中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号